Trailing-twelve-month (TTM) revenue is $785.10 Million with a year-over-year growth of +16.49%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $188,805,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-04 |
| Q4 FY2025Period ended 2025-12-31 | $197,913,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-26 |
| Q1 FY2026Period ended 2026-03-31 | $194,255,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-06 |
| Q2 FY2026Period ended 2026-06-30 | $204,128,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-29 |
| TTM revenue | $785,101,000 |
Current P/S: $9,985,432,886 market capitalization ÷ $785,101,000 TTM revenue = 12.72x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T18:55:14.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $204.13M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T18:58:27.929Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Chromatography Products | $74M | $91M | $132M | $127M | $123M | $153M |
| Filtration Products | $175M | $404M | $496M |
$785.10M
$785.10 Million
+16.49%
vs. $673.96M a year ago (TTM)
+9.08%
5 Year compound annual growth rate
1 Year
+16.49%
3 Year
+3.31%
5 Year
+9.08%
10 Year
+23.45%
15 Year
+24.91%
20 Year
+23.10%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $738.26M | +$103.82M | +16.36% |
| 2024 | $634.44M | +$2.08M | +0.33% |
| 2023 | $632.36M | ($169.17M) | (21.11%) |
| 2022 | $801.54M | +$131.00M | +19.54% |
| 2021 | $670.53M | +$304.27M | +83.08% |
| 2020 |
TTM Growth
+16.49%
3-Year CAGR
+3.31%
5-Year CAGR
+9.08%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T18:58:27.929Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $373M |
| $403M |
| Other products | $4M | $4M | $6M | $4M | $5M | $3M |
|---|
| Process Analytics Products | $33M | $48M | $54M | $57M | $59M | $81M |
|---|
| Product | $366M | $670M | $801M | $638M | $634M | $738M |
|---|
| Proteins Products | $81M | $124M | $114M | $103M | $74M | $97M |
|---|
| $366.26M |
| +$96.02M |
| +35.53% |
| 2019 | $270.25M | +$76.21M | +39.28% |
| 2018 | $194.03M | +$52.80M | +37.38% |
| 2017 | $141.24M | +$36.70M | +35.10% |
| 2016 | $104.54M | +$21.00M | +25.14% |
